← FDA DRUG APPROVALS

FDA ANDA · ANDA214023

ESTROGENS, CONJUGATED

Sponsor: NOVAST LABS

APPLICATION
ANDA214023
TYPE
ANDA
ORIGINAL APPROVAL
2025-10-15
LATEST ACTION
2025-10-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CONJUGATED ESTROGENSPrescription
ESTROGENS, CONJUGATED 1.25MG · TABLET · ORAL
CONJUGATED ESTROGENSPrescription
ESTROGENS, CONJUGATED 0.9MG · TABLET · ORAL

Approval history

2025-10-15UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →